Drug Trial Radar · NCT04196257
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 19, 2022
Primary completion
Jul 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Bio-Path Holdings, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
Conditions
- Solid Tumor, Adult
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms
- Endometrial Cancer
- Peritoneal Cancer
- Solid Tumor
Interventions
BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)Drug
Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxelDrug
Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Identify Dose Limiting Toxicity (DLT) of BP1001-ATime frame: 30 days
- Identify maximum tolerated dose (MTD) of BP1001-ATime frame: 30 days
- Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-ATime frame: 30 days
- Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A in combination with paclitaxelTime frame: 30 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Holy Cross Hospital
Silver Spring, Maryland · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.